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The prognostic value of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase
(DPD) expression, influencing the 5-fluorouracil effect, were determined in primary
tumours and node metastases of stage III colon cancer patients adjuvantly treated with 5-
fluorouracil regimens (N=391). The effect of TP53 mutation status, probably linked to TS
inhibition, was also examined.
TS and DPD protein expression was determined by immunohistochemical analysis using
tissue-microarrays and 220 of these tumours were screened previously for TP53 mutations.
Low TS protein levels in primary tumours appeared associated with mucinous histology
and low DPD protein levels with young age at time of randomisation. Concordance
between TS and DPD expression in primary and metastatic tumours was low. No
associations were found between disease-free survival (DFS) and TS or DPD protein levels.
When stratified by TP53 mutation status DFS did not differ with TS expression.
TS and DPD protein expression has no prognostic value in these patients.
INTRODUCTION
5-Fluorouracil (5-FU) has proven to be effective in the adjuvant treatment of patients with
stage III colon cancer increasing the survival rates by 15% (Moertel et al., 1995; IMPACT,
1995). The action of 5-FU mainly depends on intracellular conversion to its active
metabolite, 5-fluoro-2’-deoxyuridine-5’-monophosphate (FdUMP), which inhibits DNA
synthesis by forming a stable complex with thymidylate synthase (TS) in the presence of
folates (Pinedo and Peters, 1988). Inhibition of FdUMP by TS leads to depletion of 2’-
deoxythymidine-5’-monophosphate (dTMP) and 2’-deoxythymidine-5’-triphosphate
(dTTP), inhibiting DNA synthesis and initiating cell cycle arrest or cell death, a process in
which p53 also plays an important role (Aschele et al., 2002).
Dihydropyrimidine dehydrogenase (DPD), the first and rate-limiting enzyme in the three-
step pathway of uracil and thymine catabolism, is also important in the degradation and
inactivation of 5-FU. DPD converts over 85% of clinically administered 5-FU into the
inactive metabolite dihydrofluorouracil, a process which takes place mainly in the liver (Lu
et al., 1992).
Different therapeutic strategies, including additional administration of leucovorin (LV, 5-
formyltetrahydrofolate), have been explored to enhance the anticancer activity of 5-FU.
Leucovorin increases the intracellular levels of reduced folate, which is necessary for
optimal binding of FdUMP to TS, resulting in a prolonged inhibition of TS and
subsequently of DNA synthesis (Wright et al., 1989). Therefore, adding LV to 5-FU is
generally thought to improve the response to 5-FU and to prolong survival. TS protein also
functions as an RNA-binding protein. It can bind to its own mRNA, that of c-myc and that
of p53, thereby repressing translation (Chu et al., 1995; Ju et al., 1999). If FdUMP is bound
to TS, there is no binding possible to mRNA, resulting in an increase of TS, c-myc and p53
expression.
Several authors have shown that TS is an independent prognostic factor. High levels of
intratumoural TS expression by immunohistochemistry or RT-PCR in patients with stage
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III receiving adjuvant 5-FU-based chemotherapy, were associated with a longer overall
survival than those with low intratumoural TS expression (Johnston et al., 1994; Edler et
al., 2002; Kornmann et al., 2003). Some groups (Allegra et al., 2003; Sakamoto et al.,
2003), however, have reported a shorter overall survival in patients with high TS levels
than in patients with low TS levels, while others have found no survival difference
according to TS expression levels (Nanni et al., 2002; Allegra et al., 2002). Regarding the
predictive value of TS, several studies on advanced CRC (stage IV) showed that TS
expression levels were inversely correlated with the response rate to 5-FU-based
chemotherapy (Paradiso et al., 2000; Aschele et al., 2000; Johnston et al., 2003). They
found that a low TS expression was associated with a high response rate, particularly if
determined in metastases, rather than in primary CRCs (Aschele et al., 2000; Johnston et
al., 2003). From the results of all these studies it can be concluded that the role of TS
especially as a prognostic marker is inconclusive.
Low levels of intratumoural DPD expression have been suggested to be associated with a
high, 5-FU responsiveness (Salonga et al., 2000) or longer survival (Tokunaga et al., 2003;
Tsuji et al., 2004), while others (Kornmann et al., 2002; Ikeguchi et al., 2003) found no
prognostic advantage. In addition, a few reports (Kornmann et al., 2003; Ichikawa et al.,
2003) found that the combination of TS and DPD expression levels predicted differences in
prognosis, where Kornmann et al (2003) found that adjuvantly treated CRC patients with
high TS levels and low DPD levels had the longest survival.
Since TP53 plays a crucial role in the cellular response to 5-FU induced DNA damage and
TP53 is found mutated in about 50% of CRC, loss of functional p53 might reduce the
response to 5-FU (Lenz et al., 1998; Longley et al., 2002). TS might, therefore, well play a
pivotal role in regulating cell cycle checkpoints and apoptosis through regulation of p53
expression and other cell cycle-related proteins in response to 5-FU treatment. Suppression
of p53 by TS may abrogate G1-phase arrest and subsequently DNA repair. It is still unclear,
if this response to 5-FU regulated by TS is TP53 status dependent. In a previous study, we
determined the importance of TP53 mutation status of the tumour on the prognosis of CRC
patients. In that study we found that presence of a TP53 mutation was associated with a
shorter disease-free survival (P=0.009, Westra et al).
Since the results from the reported studies on prognostic or predictive value of TS and DPD
expression are inconclusive, we wanted to (semi) quantitatively investigate the TS and DPD
protein levels by immunohistochemical analysis of primary tumours and lymph node
metastases from stage III colon cancer patients adjuvantly treated with 5-FU-based
chemotherapy, on tissue microarrays (TMAs). In addition we determined whether the use
of leucovorin and TP53 mutation status of the primary tumour, both thought to be




Formalin-fixed paraffin-embedded primary tumour specimens from 391 patients with stage
III colon cancer from a nation-wide randomised colon trial (CKVO 90-11) were included in
this study. All patients underwent a curative resection and were randomly assigned to one
of two given adjuvant 5-FU-based chemotherapy schedules (5-FU/levamisole or 5-
FU/levamisole/leucovorin) for a period of one year, as described in more detail earlier
(Bleeker et al., 2000).
For all patients clinical and tumour characteristics were derived from the clinical database
maintained at the Comprehensive Cancer Centre North Netherlands. The mean age of all
patients at the time of randomisation was 58.7 years (range 26.2-75.8 years). Two hundred
thirteen patients (54.5%) were males. One hundred and eighty-two tumours (46.5%) were
right-sided, i.e. proximal of the splenic flexure. With regard to histological grade, 17.5 % of
the tumours were well differentiated, 57.3% moderately differentiated and 25.2% were
poorly differentiated. According to the TNM staging system, 13.6% of tumours were in
stages T1 and T2 and 86.4% in stages T3 or T4. Further, 74.2 % of the resection specimens
belonged to stage N1, while 101 (25.8%) were staged N2 (Sobin and Wittekind, 2002).
Two hundred and twenty tumours had previously been screened for TP53 mutations using
denaturing gradient gel electrophoresis (DGGE exons 4-8) and DNA sequencing (Hayes et
al., 1999). Of these, 116 showed presence of a TP53 mutation (Westra et al).
Tissue microarrays
Representative tumour tissue from all included patients were selected using hematoxylin &
eosin (H&E)-stained slides and arrayed into 5 TMAs, constructed according to standard
protocols (Hoos and Cordon-Cardo, 2001). Briefly, three 0.6 mm tissue cores were taken
from representative regions of each tumour, using the manual tissue arrayer (MTA-I) from
Beecher Instruments (Sun Prairie, USA) and these were put into a standard-size recipient
paraffin block, the TMA block. Each array contained 322 tissue cores, representing 94
tumour samples in triplicate; 10 internal controls (i.e. the same on all 5 arrays) in duplicate;
and 10 normal tissues in duplicate. In total, 5 arrays were made; four with primary tumour
samples and one with matching lymph node metastases. Four µm sections were cut from
each array block, using the paraffin tape-transfer system with adhesive-coated slides from
Instrumedics (Hackensack, USA).
Immunohistochemical analysis of TS and DPD
TS and DPD staining was performed as reported by van Triest et al (2000) and Huang et al
(2000), respectively. Briefly, the sections were deparaffinised and rehydrated. Antigen
retrieval was performed by heating the slides in a microwave oven at 750 W for 10 min in a
10 mM sodium-citrate buffer (pH 6.0), followed by cooling to room temperature for 20
min. Subsequently the sections were washed, blocked and incubated for one hour with the
primary polyclonal TS antibody (diluted at 1:100), or DPD antibody (rabbit IgG, diluted at
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1:500). They were then incubated for one hour with the secondary antibody (biotinylated
goat anti-rabbit IgG, diluted 1:300), followed by incubation with the horseradish
peroxidase-labeled avidin-biotin complex for 30 min. The antibody binding was visualised
with 3-amino-9-ethylcarbazole (AEC). Lastly, the sections were counterstained with
hematoxylin.
The immunostaining sections of TS and DPD were scored using a visual grading system of
four categories based on intensity (0 = no expression, 1 = low expression, 2 = moderate
expression, 3 = strong expression). The score was determined by the highest degree of
staining seen in the tumour tissue cores. Scoring was performed by two experienced
observers without knowledge of the clinical outcome for the patients. For discordant cases
the two observers reached consensus. Categories 0 and 1 were considered to represent low
expression; categories 2 and 3 to represent high expression (Table 1).
Statistical analyses
For comparison of distributions of continuous variables, the t-test or analysis of variance
was used. The chi-square test was used for analysis of categorical variables. Disease-free
survival (DFS) was used to assess the prognostic value of the various molecular markers, as
it is the least biased indicator of treatment failure, given the fact that disease-specific
survival might be influenced by selective use of second line treatments and overall survival
is biased due to deaths attributable to causes unrelated to colon cancer. DFS was defined as
the period from the date of randomisation to the date of the first documented relapse or to
the date of death, without documented relapse due to colon cancer, or to the date of last
contact, whichever occurred first. Censoring occurred when a patient was alive without
relapse at last contact or when the patient died of a cause other than colon cancer, not
attributable to colon cancer. Time to event curves were estimated using the product-limit
method and the survival distributions were compared with the log-rank test and the Breslow
test. For testing of concordance, the kappa coefficient and the Mc Nemar Bowker test were
used. All reported P-values are two-sided, unless stated otherwise.
RESULTS
TS and DPD protein levels in primary tumours and clinicopathological
features
The quality of the tissue microarrays in this study was good, as the rate of tissue loss was
less than 15%, which is low compared to reported rates of 15-33% of tissue damage (Hoos
and Cordon-Cardo, 2001).
The TS immunohistochemical staining was as expected with a cytoplasmic location.
Reproducibility of scoring and interpretation of TS staining was more than adequate with a
high concordance of about 80% between the observers. The quality of DPD staining was
adequate. Interpretation was more difficult as illustrated by a concordance of 65% between
the independent observers.
CHAPTER 5
Interpretable results for TS could be obtained in 90% (352/391) of the tumour samples. For
DPD analysis, 87% (341/391) of the tumour samples were informative. Fourteen percent
(48/352) of the included samples showed low TS expression (combined categories 0 and 1)
and 86% (304/352) of the primary tumour samples showed high TS expression (combined
categories 2 and 3). For DPD, 26% (88/341) of the tumour samples presented with low
expression, and 74% showed high expression. Results of immunohistochemical analyses
for TS and DPD in combination with clinicopathological features are shown in Table 1.
Low levels of TS protein were associated with mucinous histology (P=0.04) and low levels
of DPD protein were associated with younger age at time of randomisation (P=0.01; low
versus high DPD expression, 56.2 and 59.6 years, respectively). No associations with TS or
DPD were found for any of the other clinicopathological characteristics.


















N % N % N % N %
Number 48 100 304 100 88 100 253 100
Mean age (at time
of randomisation in
years)
59.0 58.5 0.746 56.2 59.6 0.010
Gender 0.070 0.755
Male 32 67 160 53 49 56 136 54
Female 16 33 144 47 39 44 117 46
Site 0.995 0.218
Proximal 22 46 138 45 46 52 113 45
Distal 26 54 166 55 42 48 140 55
Histology 0.043 0.535
Non-mucinous 27 50 218 72 57 65 179 71
Mucinous 20 42 73 24 25 28 66 26
Unknown 1 8 8 3 6 7 6 2
Differentiation 0.101 0.069
well/moderate 27 56 221 73 53 60 187 74
Poor 14 29 64 21 27 31 51 20
Unknown 7 15 18 6 8 9 15 6
Tumour invasion 0.132 0.357
Muscularis propria 3 6 43 14 13 15 28 11
Subserosa and




<4 34 71 225 74 66 75 186 74
≥4 14 29 79 26 22 25 67 26
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Survival related to TS or DPD protein levels in primary tumours
No significant associations were found between TS or DPD expression levels and disease-
free survival (P=0.17; Figure 1 and P=0.09; Figure 2, respectively). Furthermore, we did
not observe any combined effect of TS and DPD in relation to disease-free survival
(P=0.19).
Figure 1 Disease-free survival of 352 patients according to TS expression
Log-Rank test P=0.166 (Breslow: P=0.206)
Year 0 1 2 3 4 5
At risk
Number (none/low) 48 35 28 23 20 15































Figure 2 Disease-free survival of 341 patients according to DPD expression
Log-Rank test P=0.087 (Breslow: P=0.095)
Year 0 1 2 3 4 5
At risk
Number (none/low) 88 66 48 42 35 26
Number (intermediate/high) 253 192 150 122 102 79
Concordance between TS and DPD protein levels in primary tumours
and lymph node metastases
The levels of TS and DPD expression in the primary tumours were not concordant with
their expression levels in the lymph node metastases (Tables 2 and 3). The kappa
coefficients of the results of immunohistochemical staining of TS and DPD were 0.16 and
0.06, respectively. Percentages of agreement were 59% and 53%, respectively. These
agreements were considered as poor when kappa was <0.20 and as good when kappa was >
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Table 2: Concordance between TS expression in the primary tumour and in lymph node
metastases
TS consensus (lymph node)
None/low Intermediate/high
 Total
None/low 10 5 15TS consensus
(tumour) Intermediate/high 23 33 56
Total 33 38 71
Kappa coefficient 0.16 / percentage agreement 59%/  Mc Nemar-bowker P=0.001
Table 3: Concordance between DPD expression in the primary tumour and in lymph node
metastases
DPD consensus (lymph node)
None/low Intermediate/high
 Total
None/low 12 11 23DPD consensus
(tumour) Intermediate/high 21 25 46
Total 33 36 69
Kappa coefficient 0.06 / percentage agreement 53%/  Mc Nemar-bowker P=0.110
Survival related to TS or DPD expression in tumour-positive lymph
nodes
Patients whose tumours had a high expression of TS or DPD seem to show a slightly longer
survival than those whose tumours had a low expression. The log-rank test showed that this
difference in DFS, when comparing low versus high TS or DPD expression levels in the
tumour-positive lymph nodes (P=0.298; Table 4 and P=0.200; Table 5, respectively), was
not significant.








3-year DFS 5-year DFS
0.298
None/low 38 21 17.8 48.1% 41.6%
High/intermediate 41 16 19.2 65.4% 58.5%








3-year DFS 5-year DFS
0.200
None/low 38 20 16.2 50.2% 46.6%
High/intermediate 42 16 19.8 65.7% 59.8%
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Survival related to the TP53 mutation status stratified by TS protein
expression
Mutant TP53 status of the primary tumour, stratified by TS protein levels, was associated
with a worse DFS (P=0.0019; Figure 3). Although TS expression did not change the
prognostic effect of TP53 status significantly, the effect of TP53 status appeared somewhat
stronger in the group with high expression of TS protein (P=0.0001). In fact, in univariate
analysis no effect of TP53 mutation status was seen in the low TS expression group
(P=0.30), probably because the number of low TS expressing tumours was low.
Effect of leucovorin on disease-free survival of patients with low and
high TS expression in primary tumours
No survival differences were observed when we compared the low and high TS protein
levels in primary tumours of patients receiving leucovorin with 5-FU + levamisole and of
those who received 5-FU + levamisole only (log-rank P=0.20). There was also no survival
difference between patients receiving chemotherapy for less than 6 months or for 6 months
and longer, stratified by TS protein levels (log-rank P=0.44 and P=0.55, respectively).
DISCUSSION
Resistance of 5-FU in relation to TS usually depends on altered kinetics of TS, increased
dUMP level, decreased FdUMP concentration, reduced stability of the ternary complex and
intracellular depletion of folates (Pinedo and Peters, 1988; Aschele et al., 2002). Moreover,
as 80-90% of the administered dose of 5-FU is catabolised by DPD in the liver, and
consequently patients with reduced DPD activity have a high risk of severe 5-FU toxicity (
Lu et al., 1992). Since TS is the target enzyme for 5-FU and DPD is the rate-limiting
enzyme in the catabolism of 5-FU, differences in chemosensitivity of colon tumours on 5-
FU likely depend on the expression levels of TS and DPD. Therefore, TS and DPD protein
levels may predict the disease-free survival in patients treated with 5-FU regimens and
antifolates. In searching associations between clinical parameters and TS and DPD protein
levels, an association between TS and mucinous histology was noted. For DPD, an
association was found with the mean age at time of randomisation. Patients with a low
intratumoural DPD protein expression were in general about three years younger than those
with a high intratumoural DPD expression (56.2 and 59.6 years, respectively). This might
raise the question whether the suggested association of low DPD expression with longer
survival (Tokunaga et al., 2003; Tsuji et al., 2004) is due to the low DPD level proper or to
other factors associated with younger age.We did not find any prognostic significance in TS
expression. This is in agreement with several adjuvant studies (Sakamoto et al., 2003;
Nanni et al., 2002) and with results of Findlay et al (1997), who screened primary tumours
of patients with advanced disease. In our study we did not see a beneficial effect of
adjuvant therapy in patients with stage II/ III CRC and high TS protein levels, in contrast to
others (Johnston et al., 1994; Edler et al., 2002; Kornmann et al., 2003; Huang et al., 2000;
Takenoue et al., 2000).
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TP53  mutation status
mutated
wildtype
Log rank P= 0.001
(Breslow P=0.0007)






TS LOW 32 18 14
TP53 Wildtype 18 12 6 Log Rank 9.60 1 0.0019
TP53 Mutation 14 6 8
Breslow 10.86 1 0.0010
TS HIGH 169 71 98
TP53 Wildtype 76 19 57
TP53 Mutation 93 52 41
Overall 201 89 112
CHAPTER 5
Our study also did not show a prognostic relevance of intratumoural DPD expression in
adjuvantly treated patients with stage III colon cancer. This is in agreement with results
published by Kornmann et al (2002) and Ikeguchi et al (2002), but is in contradiction to
results published by others (Tokunaga et al., 2003; Tsuji et al., 2004; Ichikawa et al., 2003).
A combined TS and DPD effect was not found in our study, probably due to the many
subgroups and the quite small numbers per subgroups. We might exclude the possible
existence of a strong combined effect, since we would have detected it, even with small
numbers. Why are the results of the studies mentioned so different? A partial explanation
may be found in the way TS and DPD protein levels were determined. Another technical
explanation might be the difference in antibodies used in the different reported studies,
monoclonal (TS106 or RTSMA2) (Sakamoto et al., 2003) or polyclonal as in our study that
are recognising different epitopes (van Triest et al., 2000). A clinical explanation might be
the selection of patients that are very heterogeneous in the different studies, both with
respect to tumour stage and tumour location (in colon or rectum) and with respect to
treatment regimens (5-FU-based or other; bolus or infusional administration), in adjuvant
settings or related to advanced disease. Comparison of results of the reported studies is
therefore very difficult.
As mentioned, TP53 plays a central role in cell cycle control and apoptosis, and also seems
to be important in the response to 5-FU-induced DNA damage under TS inhibition (Lenz et
al., 1998; Longley et al., 2003). As 220 of our tumours had already been screened for TP53
mutations, we were able to investigate a possible combined effect of TP53 and TS. TS
expression levels did not change the adverse prognostic effect of TP53 that we found earlier
(Westra et al). This absence of a TS effect does not suggest an interaction between TS and
TP53, which is in line with results of others (Backus et al., 2003; Longley et al., 2003), who
found that TS inhibition in response to 5-FU as independent of TP53 status. It should be
noted, however, that the group with low intratumoural TS expression is small and that an
analysis therefore lacks the power to confirm the hypothesis that the highest response to 5-
FU, implying a longer survival, would be seen in the p53 wild-type cases in the low TS
expressing group.
The trial in which our patients participated did not show a survival benefit when leucovorin
was added to the combination of 5-FU and levamisole (Bleeker et al., 2000). We found no
effect of leucovorin on disease-free survival of patients stratified by TS expression in their
primary tumours.
When comparing expression levels of TS in primary tumours and lymph nodes, a low
concordance of 59% was found, almost equalling to the value expected on the basis of
coincidence. This agrees with results reported by others (Aschele et al., 2000; Marsh et al.,
2002). We could not confirm that high TS levels in metastases predict for non-
responsiveness to 5-FU, which normally leads to shorter survival (Aschele et al., 2000;
Salonga et al., 2000)..
In conclusion, in this adjuvantly treated group of stage III colon cancer patients TS and
DPD protein levels do not show a prognostic value. Concordance between TS and DPD
protein levels determined in the primary tumours and in the matching lymph node
metastases was low. TS protein levels did not alter the effect of either adding leucovorin in
the adjuvant treatment or the effect of TP53 mutation status, both thought to be functionally
linked to inhibition of TS activity.
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